Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Sakamoto, Y. Onoe, T. Mutoh, T. Maeda, N. Oyama, K. Hidaka (Fukuoka, Japan). Levofloxacin non-susceptible streptococcus pneumoniae in community-acquired respiratory infection; prevalence and risk factors. Eur Respir J 2007; 30: Suppl. 51, 1872

Member's Comments

No comment yet.

Related content which might interest you: S. pneumoniae community-acquired pneumonia (SP-CAP): relationship between mortality and antibiotic susceptibility and risk factors for drug resistance Source: Eur Respir J 2001; 18: Suppl. 33, 503s Year: 2001 A study of the prevalence of streptococcus pneumoniae serotypes in patients hospitalised for community-acquired pneumonia Source: International Congress 2016 – Community-acquired pneumonia: risk classes and management issues Year: 2016 Levofloxacin resistance among streptococcus pneumoniae isolates in a chronic disease hospital Source: Annual Congress 2010 - Treatment and risk factors in lower respiratory tract infections Year: 2010 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Diagnostic challenge in community-acquired pneumonia and hospital-acquired pneumonia: risk factors and diagnostic methods for methicillin resistant Staphylococcus aureus Source: Annual Congress 2006 - Methicillin resistant Staphylococcus aureus (MRSA): a real hospital-based pathogen? Year: 2006 Penicillin resistance rates for streptococcus pneumoniae strains isolated from lower respiratory tract infections Source: Eur Respir J 2002; 20: Suppl. 38, 358s Year: 2002 Community-acquired pneumonia due to streptococcus pneumoniae in hospitalized patients – mortality predictors Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests Year: 2008 Fast replicating strains of streptococcus pneumoniae are associated with severe community-acquired pneumonia Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Pulmonary disease as a risk factor for community-acquired pneumonia caused by multiple pathogens, including Streptococcus pneumoniae Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001 Streptococcus pneumoniae is the main causative agent of community-acquired pneumonia Source: Eur Respir J 2002; 20: Suppl. 38, 608s Year: 2002 Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia Source: Eur Respir J 2010; 36: 969-971 Year: 2010 Early mortality in patients with community-acquired pneumonia: causes and risk factors Source: Eur Respir J 2008; 32: 733-739 Year: 2008 Impact of initial antibiotic choice on mortality from pneumococcal pneumonia Source: Eur Respir J 2006; 27: 1010-1019 Year: 2006 MRSA as a cause of lung infection including airway infection, community-acquired pneumonia and hospital-acquired pneumonia Source: Eur Respir J 2009; 34: 1470-1476 Year: 2009 The impact of antibiotic resistance in the management of lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=131 Year: 2004 The effect of macrolide-resistance on the outcome of patients hospitalized for streptococcus pneumoniae pneumonia Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Severe Chlamydia pneumoniae community-acquired pneumonia Source: Eur Respir J 2003; 22: Suppl. 45, 545s Year: 2003 Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections Source: Eur Respir J 2002; 20: 3S-8S Year: 2002 Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review Source: Eur Respir J 2008; 31: 625-632 Year: 2008 MRSA as a cause of community-acquired pneumonia Source: Eur Respir J 2009; 34: 1013-1014 Year: 2009